Mebocaína Intensive Spray (Flurbiprofen)

Flurbiprofen works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2. This blocks the conversion of arachidonic acid into prostaglandins, which are key mediators of inflammation and pain. By lowering prostaglandin levels, flurbiprofen reduces swelling, redness, and the sensation of pain in the treated area.

The appropriate dose of Mebocaína Intensive Spray is determined by the prescribing healthcare professional based on the individual’s condition, severity of symptoms, and overall health status. Patients should follow the specific instructions provided by their prescriber and the product label, and should not alter the dose without medical guidance.

Safety data for flurbiprofen in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk, and this decision must be made by a qualified healthcare provider.

To order Mebocaína Intensive Spray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mebocaína Intensive Spray delivers flurbiprofen, a well‑studied NSAID, in an oromucosal spray format that provides rapid local action with minimal systemic exposure. Compared with other NSAID sprays, it offers a convenient dosing mechanism and a favorable safety profile when used as directed, though individual tolerability and specific formulation differences should be considered by the prescriber.

Store Mebocaína Intensive Spray at room temperature, preferably below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperatures. Keep the spray cap tightly closed when not in use and keep it out of reach of children.

The spray is applied directly to the affected area of the oral cavity or throat. The patient should tilt the head back slightly, actuate the spray as instructed by the prescriber, and avoid swallowing immediately to allow local absorption. Oral rinsing or eating should be avoided for a short period after application.

Serious risks include allergic reactions such as rash, swelling, or difficulty breathing, which require immediate medical attention. Although rare, systemic effects like gastrointestinal ulceration, renal impairment, or hepatic dysfunction can occur, especially in patients with pre‑existing conditions or when used concomitantly with other NSAIDs.

Individuals with a known hypersensitivity to flurbiprofen, other NSAIDs, or any component of the spray should avoid its use. Patients with active gastrointestinal ulcers, severe renal or hepatic disease, uncontrolled hypertension, or those taking anticoagulants without medical supervision should also refrain from using this product unless directed by a physician.